Mithra Announces Injectables Agreement with GSP

  • Mithra closes contracts with leading generics player GSP for development and supply of 4 hormonal injectables
  • Contracts should allow for European and US GMP approval of injectable section at Mithra CDMO
  • Strong validation by reputable partner of know-how and capabilities of Mithra CDMO

Liège, Belgium, 14 December 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces an agreement with GSP for the injectables section of the Mithra CDMO. The umbrella agreement comprises the development and production of four products. GSP (Generic Speciality Pharma), based in Northern Dublin (Ireland), is a leading player in generic healthcare products. The company, part of the Alter Pharma group, works with 3rd party manufacturers in a large number of geographies and outlicenses its product portfolio to partners worldwide.